Lineage Cell Therapeutics
LCTX • AMEX
Lineage Cell Therapeutics is a biotechnology company in the healthcare sector trading on AMEX, led by CEO Brian Culley, with a market cap of $371.1M.
CEOBrian Culley
Next Earnings
Upcoming earnings announcement for Lineage Cell Therapeutics
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.02
Revenue Estimate
$3.7M
Earnings History
Past 12 earnings reports for Lineage Cell Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | $0.00Est: -$0.05 | +108.0% | $6.6MEst: $2.1M | +214.9% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.13Est: -$0.02 | -550.0% | $3.7MEst: $2.4M | +51.8% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.07Est: -$0.02 | -250.0% | $2.8MEst: $1.5M | +82.4% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.02Est: -$0.03 | +33.3% | $1.5MEst: $1.7M | -12.7% | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$0.02Est: -$0.03 | +33.3% | $2.9MEst: $1.6M | +79.0% | 10-K |
| Nov 14, 2024 | Q3 2024 | -$0.02Est: -$0.03 | +33.3% | $3.8MEst: $886.6K | +326.2% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.03Est: -$0.04 | +25.0% | $1.4MEst: $970.0K | +45.2% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.04Est: -$0.04 | 0.0% | $1.4MEst: $1.4M | +6.2% | 10-Q |
| Mar 7, 2024 | Q4 2023 | -$0.03Est: -$0.04 | +25.0% | $2.1MEst: $1.3M | +60.3% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.04Est: -$0.04 | 0.0% | $1.2MEst: $2.6M | -51.9% | — |
| Aug 10, 2023 | Q2 2023 | -$0.03Est: -$0.04 | +25.0% | $3.2MEst: $2.2M | +46.6% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.03Est: -$0.04 | +25.0% | $2.4MEst: $2.0M | +18.7% | — |